Five Prime Therapeutics Inc (NASDAQ:FPRX) had its price target reduced by research analysts at Credit Suisse from $54.00 to $52.00 in a research note issued on Friday, AnalystRatings.NET reports. The firm currently has an “outperform” rating on the stock. Credit Suisse’s price objective suggests a potential upside of 55.13% from the company’s current price. A […]
